原著論文｜研究業績｜がん化学療法センター

Tanifuji R, Hosono E, Hisae Kamakura H, Muramatsu Y, Yoshida S, Sato S, Ohashi Y, Dan S, Seimiya H, Oguri H.

Strategic scaffold redesign of ecteinascidins: An approach for generating anticancer macrocycles.
Chem (in press).

Li H, Jia G, Zhang N, Fan R, Jia W, Jin M, Dan S, Zhao W, Jiang Y, and Kong D.

Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.
Med Oncol. 2025;42(7):235.

Ogawa A, Izumikawa K, Tate S, Isoyama S, Mori M, Fujiwara K, Watanabe S, Ohga T, Jo U, Taniyama D, Kitajima S, Tanaka S, Onji H, Kageyama S, I, Yamamoto G, Saito H, Morita T, Y, Okada M.

SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis.
Mol Cell. 2025;85(5):894-912.

Watanabe K, Yamamoto T, Fujita T, Hino S, Hino Y, Yamazaki K, Ohashi Y, Sakuraba S, Kono H, Nakao M, Ochiai K, Dan S, Saitoh N.

Metabolically inducing defects in DNA repair sensitizes BRCA-wild-type cancer cells to replication stress.
Sci Signal. 2024;17(862):eadl6445.

Lin Y, Itoh H, Dan S, Inoue M..

Methyl scanning approach for enhancing the biological activity of the linear peptidic natural product, efrapeptin C.
Chem Sci. 2024;15(46):19390-19399.

Kojima Y, Fujieda S, Zhou L, Takikawa M, Kuramochi K, Furuya T, Mizumoto A, Kagaya N, Kawahara T, Shin-Ya K, Dan S, Tomida A, Ishikawa F, Sadaie M.

Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicity.
Cancer Sci. 2024;115(9):3054-3066..

Suenaga M, Mashima T, Kawata N, Dan S, Seimiya H, Yamaguchi K.

Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer.
Cancers (Basel). 2024;16(16):2855.

Takeuchi K, Nishimura Y, Matsubara T, Isoyama S, Suzuki A, Matsuura M, Dan S.

Prediction of cell cycle distribution after drug exposure by high content imaging analysis using low-toxic DNA staining dye.
Pharmacol Res Perspect. 2024;12(3):e120.

Peng X, Huang X, Lulu TB, Jia W, Zhang S, Cohen L, Huang S, Fan J, Chen X, Liu S, Wang Y, Wang K, Isoyama S, Dan S, Wang F, Zhang Z, Elkabets M, Kong D.

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.
Mol Cancer. 2024;23(1):54.

Hanaki Y, Shikata Y, Kikumori M, Okamura M, Dan S, Imoto M, Irie K.

In vivo anti-cancer activity of 10-methyl-aplog-1, a simplified analog of aplysiatoxin, and its possible signaling pathway associated with G1 arrest.
Biochem Biophys Res Commun. 2023;675:19-25.

Kawatani M, Aono H, Hiranuma S, Shimizu T, Muroi M, Nogawa T, Ohishi T, Ohba SI, Kawada M, Yamazaki K, Dan S, Dohmae N, Osada H.

Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling.
Oncology Research 2023;31(6):833-844.

Zhang D, Shimokawa T, Guo Q, Dan S, Miki Y, Sunada S.

Discovery of novel DNA-damaging agents through phenotypic screening for DNA double-strand break.
Cancer Sci. 2023;114(3):1108-1117.

Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi SI, Dan S.

Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
Cell Death Dis. 2023;14(2):169.

Hosomi H, Akatsuka A, Dan S, Iwasaki H, Nambu H, Kojima N.

Synthesis of Acetogenin Analogs Comprising Pyrimidine Moieties Linked by Amine Bonds and Their Inhibitory Activity against Human Cancer Cell Lines.
Chem Pharm Bull (Tokyo). 2022;70(11):823-826.

Kunimasa K, Ikeda-Ishikawa C, Tani Y, Tsukahara S, Sakurai J, Okamoto Y, Koido M, Dan S, Tomida A.

Spautin-1 inhibits mitochondrial complex I and leads to suppression of the unfolded protein response and cell survival during glucose starvation.
Sci Rep. 2022;12(1):11533.

Xue YW, Itoh H, Dan S, Inoue M.

Gramicidin A accumulates in mitochondria, reduces ATP levels, induces mitophagy, and inhibits cancer cell growth.
Chem. Sci. 2022;13 (25):7482-7491.

Kurisawa N, Iwasaki A, Teranuma K, Dan S, Toyoshima C, Hashimoto M, Suenaga K.

Structural Determination, Total Synthesis, and Biological Activity of Iezoside, a Highly Potent Ca2+-ATPase Inhibitor from the Marine Cyanobacterium Leptochromothrix valpauliae.
J Am Chem Soc. 2022;144(24):11019-11032.

Ohta K, Fushimi T, Okamura M, Akatsuka A, Dan S, Iwasaki H, Yamashita M, Kojima N.

Structure-antitumor activity relationship of hybrid acetogenins focusing on connecting groups between heterocycles and the linker moiety.
RSC Adv. 2022;12(25):15728-15739.

Nakaya T, Aizawa K, Taguchi Y, Tsuji K, Sekine S, Murakami K, Kasai M, Nakano H, Kondoh Y, Dan S, Yoshimori A, Kouji H, Takehara D, Suzuki T, Osada H, Murata M, Tanaka A, Nagai R.

Development of low-molecular-weight compounds targeting the cancer-associated KLF5 transcription factor.
ACS Med Chem Lett. 2022;13(4):687-694.

Yoshida Y, Yuki K, Dan S, Yamazaki K, Noda M.

Suppression of tumor metastasis by a RECK-activating small molecule.
Sci Rep. 2022;12(1):2319.

Kohda Y, Sakamoto S, Umekita M, Kimura T, Kubota Y, Arisaka R, Shibuya Y, Muramatsu H, Sawa R, Dan S, Kawada M, Igarashi M.

Isolation of new derivatives of the 20-membered macrodiolide bispolide from Kitasatospora sp. MG372-hF19.
J Antibiot (Tokyo). 2022;75(2):77-85.

Yoshida J, Ohishi T, Abe H, Ohba SI, Inoue H, Usami I, Amemiya M, Oriez R, Sakashita C, Dan S, Sugawara M, Kawaguchi T, Ueno J, Asano Y, Ikeda A, Takamatsu M, Amori G, Kondoh Y, Honda K, Osada H, Noda T, Watanabe T, Shimizu T, Shibasaki M, Kawada M.

Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment.
iScience. 2021;24(12):103497.

Kawatani M, Aono H, Shimizu T, Ohkura S, Hiranuma S, Muroi M, Ogawa N, Ohishi T, Ohba S, Kawada M, Yamazaki K, Dan S, Osada H.

Identification of dihydroorotate dehydrogenase inhibitors?indoluidins?that inhibit cancer cell growth.
ACS Chem. Biol. 2021; 16 (11): 2570-2580.

Ohta K, Akatsuka A, Dan S, Iwasaki H, Yamashita M, Kojima N.

Structure-Activity Relationships of Thiophene Carboxamide Annonaceous Acetogenin Analogs: Shortening the Alkyl Chain in the Tail Part Significantly Affects Their Growth Inhibitory Activity against Human Cancer Cell Lines.
Chem Pharm Bull (Tokyo). 2021;69(10):1029-1033.

Isoyama S, Mori S, Sugiyama D, Kojima Y, Tada Y, Shitara K, Hinohara K, Dan S, Nishikawa H.

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
J Immunother Cancer. 2021;9(8):e002279.

Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y.

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
Cancer Sci. 2021;112(5):1963-1974.

Hikita K, Yamakage Y, Okunaga H, Motoyama Y, Matsuyama H, Matsuoka K, Murata T, Nakayoshi T, Oda A, Kato K, Tanaka H, Asao N, Dan S, Kaneda N.

(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
Bioorg Med Chem. 2021;30:115904.

Gonda A, Takada K, Yanagita RC, Dan S, Irie K.

Effects of side chain length of 10-methyl-aplog-1, a simplified analog of debromoaplysiatoxin, on PKC binding, anti-proliferative, and pro-inflammatory activities.
Biosci Biotechnol Biochem. 2021;85(1):168-180.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, Yamaguchi K.

Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer.
Int J Colorectal Dis. 2021;36(1):131-139.

Tsukada K, Shinki S, Kaneko A, Murakami K, Irie K, Murai M, Miyoshi H, Dan S, Kawaji K, Hayashi H, Kodama EN, Hori A, Salim E, Kuraishi T, Hirata N, Kanda Y, Asai T.

Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrone.
Nat Commun. 2020;11(1):1830.

Matsumoto T, Akatsuka A, Dan S, Iwasaki H, Yamashita M, Kojima N.

Synthesis and cancer cell growth inhibition effects of acetogenin analogs bearing ethylene glycol units for enhancing the water solubility.
Tetrahedron. 2020; 76 (13):131058.

Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ.

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.
Cancer Sci. 2020;111(2):441-450.

Kitajima Y, Ishii T, Kohda T, Ishizuka M, Yamazaki K, Nishimura Y, Tanaka T, Dan S, Nakajima M.

Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis.
Sci Rep. 2019;9 (1):8666.

Kodaka A, Hayakawa Y, AlSayegh R, J, Yasuhara T, Tomoda H, Oku T, Dan S, Tsuiji M, Tsuji T.

Stereoisomer specific induction of G2/M phase arrest and apoptosis by 9-(E, Z)-hydroxyoctadecadienoic acid in mouse lymphoma cells.
Biol Pharm Bull. 2019;42 (6):937-943.

Kamata H, Sadahiro S, Yamori T.

Discovery of inhibitors of membrane traffic from a panel of clinically effective anticancer drugs.
Biol Pharm Bull. 2019; 42 (5): 814-818.

Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, Okuyama H, Okami J, Imamura F, Ohue M, Kato K, Nomura T, Kohara A, Mori S, Dan S, Inoue M.

High-throughput screening in colorectal cancer tissue-originated spheroids.
Cancer Sci. 2019;110(1):345-355.

Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H.

Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells.
Sci Rep. 2018;8 (1): 14827.

Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, Yamazaki K, Tanaka M, Nakamura T, Semba K, Yamori T, Yaguchi SI, Dan S.

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.
Oncotarget. 2018;9(80):35141-35161.

Kitamura K, Itoh H, Sakurai K, Dan S, Inoue M.

Target Identification of Yaku'amide B and Its Two Distinct Activities against Mitochondrial FoF1-ATP Synthase.
J Am Chem Soc. 2018;140(38):12189-12199.

Hayakawa K, Hanaki Y, Tokuda H, Yanagita R, C, Nakagawa Y, Okamura M, Dan S, Irie K.

Synthesis and biological activities of acetal analogs at position 3 of 10-methyl-aplog-1, a potential anti-cancer lead derived form debromoaplysiatoxin.
Heterocycles 2018 97 (1): 478-492.

Kawasaki N, Isogaya K, Dan S, Yamori T, Takano H, Yao R, Morishita Y, Taguchi L, Morikawa M, Heldin CH, Noda T, Ehata S, Miyazono K, Koinuma D.

TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling.
Cell Discov. 2018;4:1.

Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S.

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.
Oncotarget. 2018;9(2):1641-1655.

Benabdi S, Peurois F, Nawrotek A, Chikireddy J, Ca?eque T, Yamori T, Shiina I, Ohashi Y, Dan S,
Rodriguez R, Cherfils J, Zeghouf M.

Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles.
Biochemistry 2017;56(38):5125-5133.

Hanaki Y, Kikumori M, Tokuda H, Okamura M, Dan S, Adachi N, Saito N, Yanagita RC, Irie K.

Loss of the Phenolic Hydroxyl Group and Aromaticity from the Side Chain of Anti-Proliferative 10-Methyl-aplog-1, a Simplified Analog of Aplysiatoxin, Enhances Its Tumor-Promoting and Proinflammatory Activities.
Molecules 2017;22(4):631.

Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H.

Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole
Sci Rep 2017; 7 (1): 3605.

Matsumoto T, Kojima N, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.

Convergent synthesis of stereoisomers of THF ring moiety of acetogenin thiophene analogue and their antiproliferative activities against human cancer cell lines.
Tetrahedron 2017; 73 (17): 2359-2366.

Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.

M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
Cancer Res. 2016;76(13):3895-3903..

Akatsuka A, Kojima N, Okamura M, Dan S, Yamori T.

A novel thiophene-3-carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I.
Pharmacol Res Perspect. 2016;4(4):e00246..

Uesugi S, Fujisawa N, Yoshida J, Watanabe M, Dan S, Yamori T, Shiono Y, Kimura K.

Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition.
J Antibiot (Tokyo). 2016;69(3):133-140..

Takemoto Y, Ito A, Niwa H, Okamura M, Fujiwara T, Hirano T, Handa N, Umehara T, Sonoda T, Ogawa K, Tariq M, Nishino N, Dan S, Kagechika H, Yamori T, Yokoyama S, Yoshida M.

Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
J Med Chem. 2016;59(8):3650-3660..

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Oncotarget. 2016;7(23):34811-34823..

Okada M, Mei ZW, Hossain MI, Tominaga T, Takebayashi T, Murakami M, Yasuda M, Shigehiro T, Kasai T, Mizutani A, Murakami H, El Sayed Iel T, Dan S, Yamori T, Seno M, Inokuchi T.

Synthesis and in vitro cancer cell growth inhibition evaluation of 11-amino-modified 5-Me-indolo[2,3-b]quinolines and their COMPARE analyses.
Med Chem Res. 2016;25(5):879-892..

Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
Eur J Med Chem. 2016;121:592-609..

Narita K, Katoh Y, Ojima K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Total Synthesis of the Depsipeptide FR901375 and Preliminary Evaluation of Its Biological Activity.
European Journal of Organic Chemistry 2016;34:5667-5677..

Matsumoto Y, Tsujimoto H, Ono S, Shinomiya N, Miyazaki H, Hiraki S, Takahata R, Yoshida K, Saitoh D, Yamori T, Yamamoto J, Hase K.

Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model.
Ann Surg Oncol. 2016;23 Suppl 2:257-265..

Hattori T, Watanabe-Takahashi M, Shiina I, Ohashi Y, Dan S, Nishikawa K, Yamori T, Naito M.

M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.
Genes Cells. 2016;21(8):901-906..

Isoyama S, Kajiwara G, Tamaki N, Okamura M, Yoshimi H, Nakamura N, Kawamura K, Nishimura Y, Namatame N, Yamori T, Dan S.

Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Cancer Sci. 2015;106(2):171-178.

Morita M, Ogawa H, Ohno O, Yamori T, Suenaga K, Toyoshima C.

Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca(2+) pumps with a unique mode of binding.
FEBS Lett. 2015;589(13):1406-1411.

Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A.

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Cancer Sci. 2015;106(7):909-920.

Kojima N, Suga Y, Matsumoto T, Tanaka T, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.

Synthesis of dansyl-labeled probe of thiophene analogue of annonaceous acetogenins for visualization of cell distribution and growth inhibitory activity toward human cancer cell lines.
Bioorg Med Chem. 2015;23(6):1276-1283.

Kawada M, Inoue H, Ohba S, Yoshida J, Masuda T, Yamasaki M, Usami I, Sakamoto S, Abe H, Watanabe T, Yamori T, Shibasaki M, Nomoto A.

Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction.
PLoS One. 2015;10(3):e0119415.

Iwasaki A, Ohno O, Katsuyama S, Morita M, Sasazawa Y, Dan S, Simizu S, Yamori T, Suenaga K.

Identification of a molecular target of kurahyne, an apoptosis-inducing lipopeptide from marine cyanobacterial assemblages.
Bioorg Med Chem Lett. 2015;25(22):5295-5298.

Ikeda K, Kamisuki S, Uetake S, Mizusawa A, Ota N, Sasaki T, Tsukuda S, Kusayanagi T, Takakusagi Y, Morohashi K, Yamori T, Dan S, Shiina I, Sugawara F.

Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factors.
Bioorg Med Chem. 2015;23(18):6118-6124.

Horii R, Matsuura M, Dan S, Ushijima M, Uehiro N, Ogiya A, Honma N, Ito Y, Iwase T, Yamori T, Akiyama F.

Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.
Int J Clin Oncol. 2015;20(3):490-498.

Chen X, Tang SA, Lee E, Qiu Y, Wang R, Duan HQ, Dan S, Jin M, Kong D.

IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-kappaB and MAPK inactivation in RAW264.7 cells.
Life Sci. 2015;124:8-15.

Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H, Takagi R, Shimizu T, Yamori T, Osada H, Noda T.

A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells.
Oncogene. 2014;33(33):4242-4252.

Tang SA, Zhou Q, Guo WZ, Qiu Y, Wang R, Jin M, Zhang W, Li K, Yamori T, Dan S, Kong D.

In vitro antitumor activity of stellettin B, a triterpene from marine sponge Jaspis stellifera, on human glioblastoma cancer SF295 cells.
Mar Drugs. 2014;12(7):4200-4213.

Momose I, Abe H, Watanabe T, Ohba S, Yamazaki K, Dan S, Yamori T, Masuda T, Nomoto A.

Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Cancer Sci. 2014;105(12):1609-1615.

Kong D, Yamori T, Yamazaki K, Dan S.

In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Invest New Drugs. 2014;32(6):1134-1143.

Kojima N, Fushimi T, Tatsukawa T, Tanaka T, Okamura M, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.

Thiophene-3-carboxamide analogue of annonaceous acetogenins as antitumor drug lead.
Eur J Med Chem. 2014;86C:684-689.

Jin M, Zhou Q, Lee E, Dan S, Duan HQ, Kong D.

AS252424, a PI3Kgamma Inhibitor, Downregulates Inflammatory Responsiveness in Mouse Bone Marrow-Derived Mast Cells.
Inflammation. 2014;37(4):1254-1260.

Fukui Y, Narita K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity.
Eur J Med Chem. 2014;76:301-313.

Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I.

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Mol Cancer Ther. 2014;13(11):2653-2661.

Guo, W.Z., Shiina, I., Wang, Y., Umeda, E., Watanabe, C., Uetake, S., Ohashi, Y., Yamori, T., Dan, S.

Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.
Biochem Pharmacol, 86, 1272-1284 (2013)

Guo, W.Z., Wang, Y., Umeda, E., Shiina, I., Dan, S., Yamori, T.

Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.
Biol Pharm Bull, 36, 1008-1016 (2013)

Hossain, M.I., Switalska, M., Peng, W., Takashima, M., Wang, N., Kaise, M., Wietrzyk, J., Dan, S., Yamori, T., Inokuchi, T.

Design, synthesis, and in vitro cancer cell growth inhibition evaluation and antimalarial testing of trioxanes installed in cyclic 2-enoate substructures.
Eur J Med Chem, 69C, 294-309 (2013)

Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-Hara, T., Song, Y., Engelman, J.A., Fujita, N.

Cytotoxic activity of Tivanitib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73, 3087-3096 (2013)

Kojima, N., Fushimi, T., Tatsukawa, T., Yoshimitsu, T., Tanaka, T., Yamori, T., Dan, S., Iwasaki, H., Yamashita, M.

Structure-activity relationships of hybrid annonaceous acetogenins: powerful growth inhibitory effects of their connecting groups between heterocycle and hydrophobic carbon chain bearing THF ring on human cancer cell lines.
Eur J Med Chem, 63, 833-839 (2013)

Komeda, S., Takayama, H., Suzuki, T., Odani, A., Yamori, T., Chikuma, M.

Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Metallomics, 5, 461-468 (2013)

Nagahara, Y., Takeyoshi, M., Sakemoto, S., Shiina, I., Nakata, K., Fujimori, K., Wang, Y., Umeda, E., Watanabe, C., Uetake, S., Yamori, T., Dan, S., Yoshimi, Y., Shinomiya, T., Ikekita, M.

Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement.
Biochem Biophys Res Commun, 435, 657-663 (2013)

Narita, K., Fukui, Y., Sano, Y., Yamori, T., Ito, A., Yoshida, M., Katoh, T.

Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities.
Eur J Med Chem, 60, 295-304 (2013)

Obuchi, W., Ohtsuki, S., Uchida, Y., Ohmine, K., Yamori, T., Terasaki, T.

Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics.
Mol Pharmacol, 83, 490-500 (2013)

Shiina, I., Umezaki, Y., Ohashi, Y., Yamazaki, Y., Dan, S., Yamori, T.

Total synthesis and anticancer activity of AMF-26 targeting ADP-ribosylation factor 1 (Arf1).
J Med Chem, 56, 150-159 (2013)

Ushijima, M., Mashima, T., Tomida, A., Dan, S., Saito, S., Furuno, A., Tsukahara, S., Seimiya, H., Yamori, T., Matsuura, M.

Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.
Cancer Sci, 104, 360-368 (2013)

Isoyama, S., Dan, S., Nishimura, Y., Nakamura, N., Kajiwara, G., Seki, M., Irimura, T., Yamori, T.

Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Cancer Sci, 103, 1955-1960 (2012)

Dan, S., Okamura, M., Mukai, Y., Yoshimi, H., Inoue, Y., Hanyu, A., Sakaue-Sawano, A., Imamura, T., Miyawaki, A., Yamori, T.

ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Eur J Cancer, 48, 936-943 (2012)

Haruta, K., Mori, S., Tamura, N., Sasaki, A., Nagamine, M., Yaguchi, S., Kamachi, F., Enami, J., Kobayashi, S., Yamori, T., Takasaki, Y.

Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.
Inflamm Res, 61, 551-562 (2012)

Isoyama, S., Yoshimi, H., Dan, S., Okamura, M., Seki, M., Irimura, T., Yamori, T.

Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Biol Pharm Bull, 35, 1607-1613 (2012)

Kaneko, M., Matsuda, D., Ohtawa, M., Fukuda, T., Nagamitsu, T., Yamori, T., Tomoda, H.

Potentiation of bleomycin in jurkat cells by fungal pycnidione.
Biol Pharm Bull, 35, 18-28 (2012)

Kimura, K., Sakamoto, Y., Fujisawa, N., Uesugi, S., Aburai, N., Kawada, M., Ohba, S., Yamori, T., Tsuchiya, E., Koshino, H.

Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
Bioorg Med Chem, 20, 3887-3897 (2012)

Kong, D., Yamori, T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg Med Chem, 20, 1947-1951 (2012)

Miyazaki, T., Pan, Y., Joshi, K., Purohit, D., Hu, B., Demir, H., Mazumder, S., Okabe, S., Yamori, T., Viapiano, M., Shin-ya, K., Seimiya, H., Nakano, I.

Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
Clin Cancer Res, 18, 1268-1280 (2012)

Morita, M., Ohno, O., Teruya, T., Yamori, T., Inuzuka, T., Suenaga, K.

Isolation and structures of biselyngbyasides B, C, and D from the marine cyanobacterium Lyngbya sp., and the biological activities of biselyngbyasides.
Tetrahedron, 68, 5984-5990 (2012)

Ohashi, Y., Iijima, H., Yamaotsu, N., Yamazaki, K., Sato, S., Okamura, M., Sugimoto, K., Dan, S., Hirono, S., Yamori, T.

AMF-26: a novel inhibitor of the Golgi system, targeting Arf1, an ADP-ribosylation factor 1, with potential for cancer therapy.
J Biol Chem, 287, 3885-3897 (2012)

Yao, R., Natsume, Y., Saiki, Y., Shioya, H., Takeuchi, K., Yamori, T., Toki, H., Aoki, I., Saga, T., Noda, T.

Disruption of Tacc3 function leads to in vivo tumor regression.
Oncogene, 31, 135-148 (2012)

Anzai, K., Sekine-Suzuki, E., Ueno, M., Okamura, M., Yoshimi, H., Dan, S., Yaguchi, S.I., Enami, J., Yamori, T., Okayasu, R.

Effectiveness of combined treatment of X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo.
Cancer Sci, 102, 1176-1180 (2011)

Awale, S., Linn, T.Z., Li, F., Tezuka, Y., Myint, A., Tomida, A., Yamori, T., Esumi, H., Kadota, S.

Identification of Chrysoplenetin from Vitex negundo as a Potential Cytotoxic Agent against PANC-1 and a Panel of 39 Human Cancer Cell Lines (JFCR-39).
Phytother Res, 25, 1770-1775 (2011)

Donev, I.S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., Yano, S.

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Clin Cancer Res, 17, 2260-2269 (2011)

Fuwa, H., Suzuki, T., Kubo, H., Yamori, T., Sasaki, M.

Total synthesis and biological assessment of (-)-exiguolide and analogues.
Chemistry, 17, 2678-2688 (2011)

Kojima, N., Suga, Y., Hayashi, H., Yamori, T., Yoshimitsu, T., Tanaka, T.

Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines.
Bioorg Med Chem Lett, 21, 5745-5749 (2011)

Kong, D., Yamori, T., Kobayashi, M., Duan, H.

Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone.
Mar Drugs, 9, 154-161 (2011)

Kong, D., Zhang, Y., Yamori, T., Duan, H., Jin, M.

Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms.
Molecules, 16, 5159-5167 (2011)

Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M.R., Yamori, T., Nishiyama, N., Kataoka, K.

Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting.
Sci Transl Med, 3, 64ra62 (2011)

Kojima, N., Morioka, T., Urabe, D., Yano, M., Suga, Y., Maezaki, N., Ohashi-Kobayashi, A., Fujimoto, Y., Maeda, M., Yamori, T., Yoshimitsu, T., Tanaka, T.

Convergent synthesis of fluorescence-labeled probes of Annonaceous acetogenins and visualization of their cell distribution.
Bioorg Med Chem, 18, 8630-8641 (2010)

Koyama, J., Morita, I., Yamori, T.

Correlation between cytotoxic activities and reduction potentials of heterocyclic quinones.
Molecules, 15, 6559-6569 (2010)

Laroche-Clary, A., Le Morvan, V., Yamori, T., Robert, J.

Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models.
Mol Cancer Ther, 9, 3315-3321 (2010)

Ueoka, R., Ise, Y., Ohtsuka, S., Okada, S., Yamori, T., Matsunaga, S.

Yaku'amides A and B, cytotoxic linear peptides rich in dehydroamino acids from the marine sponge Ceratopsion sp.
J Am Chem Soc, 132, 17692-17694 (2010)

Chou, L.C., Chen, C.T., Lee, J.C., Way, T.D., Huang, C.H., Huang, S.M., Teng, C.M., Yamori, T., Wu, T.S., Sun, C.M., Chien, D.S., Qian, K., Morris-Natschke, S.L., Lee, K.H., Huang, L.J., Kuo, S.C.

Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent.
J Med Chem, 53, 1616-1626 (2010)

Dan, S., Okamura, M., Seki, M., Yamazaki, K., Sugita, H., Okui, M., Mukai, Y., Nishimura, H., Asaka, R., Nomura, K., Ishikawa, Y., Yamori, T.

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Cancer Res, 70, 4982-4994 (2010)

Hiramatsu, M., Ninomiya, H., Inamura, K., Nomura, K., Takeuchi, K., Satoh, Y., Okumura, S., Nakagawa, K., Yamori, T., Matsuura, M., Morikawa, T., Ishikawa, Y.

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Lung Cancer, 70, 94-102 (2010)

Ihara, Y., Kihara, Y., Hamano, F., Yanagida, K., Morishita, Y., Kunita, A., Yamori, T., Fukayama, M., Aburatani, H., Shimizu, T., Ishii, S.

The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor.
Proc Natl Acad Sci U S A, 107, 17309-17314 (2010)

Kong, D., Dan, S., Yamazaki, K., Yamori, T.

Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Eur J Cancer, 46, 1111-1121 (2010)

Kong, D., Yamazaki, K., Yamori, T.

Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library.
Biol Pharm Bull, 33, 1600-1604 (2010)

Momose, I., Ohba, S., Tatsuda, D., Kawada, M., Masuda, T., Tsujiuchi, G., Yamori, T., Esumi, H., Ikeda, D.

Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
Biochem Biophys Res Commun, 392, 460-466 (2010)

Toyama, S., Tamura, N., Haruta, K., Karakida, T., Mori, S., Watanabe, T., Yamori, T., Takasaki, Y.

Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
Arthritis Res Ther, 12, R92 (2010)

Yokosuka, A., Sato, K., Yamori, T., Mimaki, Y.

Triterpene glycosides from Curculigo orchioides and their cytotoxic activity.
J Nat Prod, 73, 1102-1106 (2010)

Akashi, T., Yamori, T.

Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS.
Proteome Sci, 7, 14 (2009)

Dan, S., Yoshimi, H., Okamura, M., Mukai, Y., Yamori, T.

Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Biochem Biophys Res Commun, 379, 104-109 (2009)

Faur, N., Araud, L., Laroche-Clary, A., Kanno, J., Toutain, J., Yamori, T., Robert, J., Le Morvan, V.

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.
Br J Cancer, 101, 350-356 (2009)

Kong, D., Okamura, M., Yoshimi, H., Yamori, T.

Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Eur J Cancer, 45, 857-865 (2009)

Kong, D., Yaguchi, S., Yamori, T.

Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Biol Pharm Bull, 32, 297-300 (2009)

Nakamura, T., Nakatsu, N., Yoshida, Y., Yamazaki, K., Dan, S., Sadahiro, S., Makuuchi, H., Yamori, T.

Identification of Candidate Genes Determining Chemosensitivity to Anti-cancer Drugs of Gastric Cancer Cell Lines.
Biological & Pharmaceutical Bulletin, 32, 1936-1939 (2009)

Narita, K., Kikuchi, T., Watanabe, K., Takizawa, T., Oguchi, T., Kudo, K., Matsuhara, K., Abe, H., Yamori, T., Yoshida, M., Katoh, T.

Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
Chemistry, 15, 11174-11186 (2009)

Nomura, T., Uehara, Y., Kawajiri, H., Ryoyama, K., Yamori, T., Fuke, Y.

Alkyl isothiocyanates suppress epidermal growth factor receptor kinase activity but augment tyrosine kinase activity.
Cancer Epidemiol, 33, 288-292 (2009)

Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., Miyata, N.

Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
J Med Chem, 52, 2909-2922 (2009)

Takahata, M., Inoue, Y., Tsuda, H., Imoto, I., Koinuma, D., Hayashi, M., Ichikura, T., Yamori, T., Nagasaki, K., Yoshida, M., Matsuoka, M., Morishita, K., Yuki, K., Hanyu, A., Miyazawa, K., Inazawa, J., Miyazono, K., Imamura, T.

SKI and MEL1 cooperate to inhibit transforming growth factor-β signal in gastric cancer cells.
J Biol Chem, 284, 3334-3344 (2009)

Chen, C.J., Hsu, M.H., Huang, L.J., Yamori, T., Chung, J.G., Lee, F.Y., Teng, C.M., Kuo, S.C.

Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.
Biochem Pharmacol, 75, 360-368 (2008)

Kojima, N., Fushimi, T., Maezaki, N., Tanaka, T., Yamori, T.

Synthesis of hybrid acetogenins, alpha,beta-unsaturated-gamma-lactone-free nitrogen-containing heterocyclic analogues, and their cytotoxicity against human cancer cell lines.
Bioorg Med Chem Lett, 18, 1637-1641 (2008)

Kojima, N., Hayashi, H., Suzuki, S., Tominaga, H., Maezaki, N., Tanaka, T., Yamori, T.

Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines.
Bioorg Med Chem Lett, 18, 6451-6453 (2008)

Saito, H., Minamisawa, T., Yamori, T., Shiba, K.

Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria.
Cancer Sci, 99, 398-406 (2008)

Shiina, I., Sano, Y., Nakata, K., Kikuchi, T., Sasaki, A., Ikekita, M., Nagahara, Y., Hasome, Y., Yamori, T., Yamazaki, K.

Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents.
Biochem Pharmacol, 75, 1014-1026 (2008)

Sugita, H., Dan, S., Kong, D., Tomida, A., Yamori, T.

A new evaluation method for quantifying PI3K activity by HTRF assay.
Biochem Biophys Res Commun, 377, 941-945 (2008)

Wang, L., Bai, L., Tokunaga, D., Watanabe, Y., Hasegawa, T., Sakai, J., Tang, W., Bai, Y., Hirose, K., Yamori, T., Tomida, A., Tsuruo, T., Ando, M.

The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity.
J Wood Sci, 54, 390-401 (2008)

Akashi, T., Nishimura, Y., Wakatabe, R., Shiwa, M., Yamori, T.

Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Biochem Biophys Res Commun, 352, 514-521 (2007)

Akashi, T., Yamori, T.

A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins.
Proteomics, 7, 2350-2354 (2007)

Amagata, T., Tanaka, M., Yamada, T., Doi, M., Minoura, K., Ohishi, H., Yamori, T., Numata, A.

Variation in cytostatic constituents of a sponge-derived Gymnascella dankaliensis by manipulating the carbon source.
J Nat Prod, 70, 1731-1740 (2007)

Araki, H., Inoue, M., Suzuki, T., Yamori, T., Kohno, M., Watanabe, K., Abe, H., Katoh, T.

Enantioselective Total Synthesis of (+)-Ottelione A, (-)-Ottelione B, (+)-3-epi-Ottelione A and Preliminary Evaluation of Their Antitumor Activity.
Chemistry, 13, 9866-9881 (2007)

Hasegawa, T., Bai, J., Dai, J., Bai, L., Sakai, J., Nishizawa, S., Bai, Y., Kikuchi, M., Abe, M., Yamori, T., Tomida, A., Tsuruo, T., Hirose, K., Ando, M.

Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
Bioorg Med Chem Lett, 17, 3722-3728 (2007)

Ichikawa, K., Sakabe, E., Kuninobu, K., Yamori, T., Tsuruo, T., Yao, T., Tsuneyoshi, M., Utsumi, H.

Application of in vivo ESR/spin-probe technique to monitor tumor in vivo in mouse footpad.
Antioxid Redox Signal, 9, 1699-1707 (2007)

Inoue, A., Seino, Y., Terasaka, S., Hayashi, S., Yamori, T., Tanji, M., Kiyama, R.

Comparative profiling of the gene expression for estrogen responsiveness in cultured human cell lines.
Toxicol In Vitro, 21, 741-752 (2007)

Ishizu, K., Sunose, N., Yamazaki, K., Tsuruo, T., Sadahiro, S., Makuuchi, H., Yamori, T.

Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Biol Pharm Bull, 30, 1779-1783 (2007)

Ito, H., Iwasaki, J., Sato, Y., Aoyagi, M., Iguchi, K., Yamori, T.

Marine diterpenoids with a briarane skeleton from the Okinawan soft coral Pachyclavularia violacea.
Chem Pharm Bull (Tokyo), 55, 1671-1676 (2007)

Kong, D., Yamori, T.

ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
Cancer Sci, 98, 1638-1642 (2007)

Kuroda, M., Yokosuka, A., Kobayashi, R., Jitsuno, M., Kando, H., Nosaka, K., Ishii, H., Yamori, T., Mimaki, Y.

Sesquiterpenoids and flavonoids from the aerial parts of Tithonia diversifolia and their cytotoxic activity.
Chem Pharm Bull (Tokyo), 55, 1240-1244 (2007)

Matsuo, Y., Kanoh, K., Yamori, T., Kasai, H., Katsuta, A., Adachi, K., Shin-Ya, K., Shizuri, Y.

Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. I. Fermentation, isolation and biological activities.
J Antibiot, 60, 251-255 (2007)

Matsuoka, A., Isama, K., Tanimura, S., Kohno, M., Yamori, T.

A novel candidate compound with urethane structure for anticancer drug development.
Curr Drug Discov Technol, 4, 69-76 (2007)

Nakamura, H., Dan, S., Akashi, T., Unno, M., Yamori, T.

Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR.
Biol Pharm Bull, 30, 1181-1184 (2007)

Nakatsu, N., Nakamura, T., Yamazaki, K., Sadahiro, S., Makuuchi, H., Kanno, J., Yamori, T.

Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines.
Mol Pharmacol, 72, 1171-1180 (2007)

Yamaguchi, T., Yoshida, T., Kurachi, R., Kakegawa, J., Hori, Y., Nanayama, T., Hayakawa, K., Abe, H., Takagi, K., Matsuzaki, Y., Koyama, M., Yogosawa, S., Sowa, Y., Yamori, T., Tajima, N., Sakai, T.

Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor.
Cancer Sci, 98, 1809-1816 (2007)

Yokosuka, A., Haraguchi, M., Usui, T., Kazami, S., Osada, H., Yamori, T., Mimaki, Y.

Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells.
Bioorg Med Chem Lett, 17, 3091-3094 (2007)

Kimura, H., Katoh, T., Kajimoto, T., Node, M., Hisaki, M., Sugimoto, Y., Majima, T., Uehara, Y., Yamori, T.

Modification of pyrimidine derivatives from antiviral agents to antitumor agents.
Anticancer Res, 26, 91-97 (2006)

Kishi, Y., Okudaira, S., Tanaka, M., Hama, K., Shida, D., Kitayama, J., Yamori, T., Aoki, J., Fujimaki, T., Arai, H.

Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
J Biol Chem, 281, 17492-17500 (2006)

Nakamura, H., Kuroda, H., Saito, H., Suzuki, R., Yamori, T., Maruyama, K., Haga, T.

Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors.
ChemMedChem, 1, 729-740 (2006)

Tanaka, R., Wada, S., Yamada, T., Yamori, T.

Potent antitumor activity of 3,4-seco-8βH-Ferna-4(23),9(11)-dien-3-oic acid (EC-2) and 3,4-seco-Oleana-4(23),18-dien-3-oic acid (EC-4), evaluated by an in vitro human cancer cell line panel.
Planta Med, 72, 1347-1349 (2006)

Yaguchi, S., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., Yamori, T.

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
J Natl Cancer Inst, 98, 545-556 (2006)

目次

原著論文

2025年

2024年

2023年

2022年

2021年

2020年

2019年

2018年

2017年

2016年

2015年

2014年

2013年

2012年

2011年

2010年

2009年

2008年

2007年

2006年